DMPI - DelMar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue6/30/20176/30/20166/30/20156/30/2014
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development5,003.643,360.8782,555.7542,119.217
Selling General and Administrative3,317.1892,853.142,168.8993,134.409
Non Recurring----
Others----
Total Operating Expenses8,405.9236,591.9454,724.6535,253.626
Operating Income or Loss-8,405.923-6,591.945-4,724.653-5,253.626
Income from Continuing Operations
Total Other Income/Expenses Net324.159-2,272.919376.88611,612.034
Earnings Before Interest and Taxes-8,405.923-6,591.945-4,724.653-5,253.626
Interest Expense---2.091-8.14
Income Before Tax-8,081.764-8,864.864-4,347.7676,358.408
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-8,081.764-8,864.864-4,347.7676,358.408
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-8,081.764-8,864.864-4,347.7676,358.408
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-8,872.218-9,103.19-4,347.7676,358.408